Publications by authors named "Marcin Bula"

Claim this Profile
H
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.
Leila Janani, Alasdair P S Munro, Annie Wright, Parvinder K Aley, Gavin Babbage, Marcin Bula

J Infect· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Trial of AWZ1066S, an Anti-Wolbachia Candidate Macrofilaricide.
Graham Devereux, Marcin Bula, Karen Tripp, Richard Fitzgerald, Nicola Eraut

Clin Pharmacol Drug Dev· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Ivan T Lee, Catherine A Cosgrove, Patrick Moore, Claire Bethune, Rhiannon Nally, Marcin Bula

Lancet Infect Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
Xinxue Liu, Alasdair P S Munro, Annie Wright, Shuo Feng, Leila Janani, Marcin Bula

J Infect· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Xinxue Liu, Alasdair Ps Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Marcin Bula

J Infect· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Alasdair P S Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K Aley, Marcin Bula

Lancet Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Xinxue Liu, Alasdair P S Munro, Shuo Feng, Leila Janani, Parvinder K Aley, Marcin Bula

J Infect· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Alasdair P S Munro, Leila Janani, Victoria Cornelius, Parvinder K Aley, Gavin Babbage, Marcin Bula

Lancet· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
Saye H Khoo, Richard Fitzgerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Marcin D Bula

J Antimicrob Chemother· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia.
Shampa Das, Richard Fitzgerald, Asad Ullah, Marcin Bula, Andrea M Collins

Antimicrob Agents Chemother· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis